PCSK9 and acne: As detailed in Table 6, the increase in blood LDL level driven by the PCSK9 gene, which represents exposure to alirocumab therapy, was positively linked to the risk of acne vulgaris (OR=1.782, 95%CI: 1.129, 2.812).